-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
In Vitro Killing Experimental Platform from InnoModels Biotechnology
Author:
InnoModels
Release time:
2024-09-25
In the vast field of life science and drug discovery, in vitro experimental platforms play a crucial role. As a leader in this field, InnoModels Biotechnology (Beijing) Co., Ltd. provides scientists with a highly controlled and precise experimental environment with its in vitro killing platform, which greatly facilitates the screening of new drugs, the study of drug mechanisms, and the development of immunotherapies.
Platform Overview
InnoModels' in vitro killing platform is a comprehensive experimental platform integrating multiple advanced technologies, focusing on simulating cell-cell interactions in an in vitro environment, especially the killing effect of immune cells on tumor cells. The platform ensures the accuracy and reproducibility of the experimental results by precisely controlling the experimental conditions, such as temperature, humidity and atmosphere. Meanwhile, it supports the application of multiple cell types, including tumor cells, primary cells, etc., providing researchers with a wide range of possibilities in different fields.
Platform Features
1. **Highly controllable experimental environment**: The in vitro killing experimental platform of InnoModels Biotechnology is able to precisely regulate the experimental conditions and reduce the interference of external factors to ensure the accuracy of the experimental results.
2. **Multiple cell types support**: The platform supports the application of multiple cell types, enabling researchers to carry out a wide range of studies in different fields and meet diversified experimental needs.
3. **Real-time monitoring and data analysis**: During the experiment, the platform is able to monitor the cell status and response in real-time, as well as record and analyze the data, providing researchers with comprehensive experimental results.
4. **Advanced automation technology**: Automation technology is used to optimize the experimental process, reduce experimental errors, and improve the reliability and efficiency of experiments.
Core Technology and Application
One of the core technologies of the platform is the PBMC-tumor cell co-culture killing model. The model achieves precise distinction between effector cells (immune cells) and target cells (tumor cells) by mixing cultured peripheral blood single nucleated cells (PBMCs) and tumor cells, and using CFSE-labeled tumor cells and CD45-labeled immune cells. The killing of target cells was verified by flow cytometry, which effectively reduces the influence of immune cell proliferation and apoptosis on the test results, and achieves an accurate assessment of killing.

Application Areas
The in vitro killing experimental platform of InnoModels Biotechnology has been widely used in many fields:
1. **Drug Screening**: Researchers can utilize the platform to conduct large-scale drug screening to assess the killing effect of drugs on cells, providing important data support for new drug discovery.
2. **Toxicity assessment**: It is used to assess the toxicity level of compounds or drugs, providing key information for safety assessment during drug development.
3. **Immunotherapy Research**: When researching immunotherapy, the platform can be used to assess the killing effect of immune cells on tumor cells, providing an important reference for the development and optimization of immunotherapy.
4. **Personalized Medicine**: Tailor-made treatment plans based on individual patient's immune response to improve therapeutic effects and promote the development of individualized medicine.
Company Background and Vision
Ltd. was co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Champion and Shanghai Jiao Tong University Institute of Immunology. The company has always been committed to promoting technological innovation and providing scientists with advanced experimental tools to help research and development of oncology and tumor immunotherapy. Its in vitro killing experimental platform, as one of the company's important achievements, not only provides strong support for drug discovery companies and translational medicine researchers, but also brings more therapeutic hope to tumor patients.
In the future, InnoModels Biotechnology will continue to uphold the attitude of never compromising on quality, adhere to the ethical bottom line of scientists, and dedicate itself to providing more advanced and reliable experimental platforms and technical support in the field of life science research and drug development, and promoting the continuous progress and development of the scientific field.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd